Latest Content

In today's Pharmaceutical Executive Daily, Novo Nordisk launches Wegovy HD nationwide across the U.S., Gilead Sciences agrees to acquire German antibody-drug conjugate biotech Tubulis for up to $5 billion, and Pharmaceutical Executive marks World Health Day 2026 with a collection of voices from industry leaders on what it means to stand with science.

The agentic model is emerging as a strategic tool to compress analysis timelines, coordinate cross-functional teams and surface competitive intelligence in real time.

Novo Nordisk’s U.S. launch of a higher-dose Wegovy formulation highlights Novo's effort to extend efficacy, capture broader patient demand, and reinforce its dominance in the rapidly expanding obesity market.

Gilead Sciences’ acquisition of Tubulis underscores the intensifying industry focus on antibody-drug conjugates as a key frontier in oncology treatment.

Industry leaders highlight how evidence-based decision-making remains central as World Health Day 2026 emphasizes the theme of standing with science.

GLP-1 side effects can be serious, and Phenomix CEO Mark Bagnall discusses the impact they can have on patients, who are not always fully educated.

Where PBMs fit into the new market access landscape, how pharma companies can respond and the questions that remain.

In today's Pharmaceutical Executive Daily, Neurocrine Biosciences agrees to acquire Soleno Therapeutics for $2.9 billion to gain Vykat XR, the first approved treatment for hyperphagia in Prader-Willi syndrome, BioNTech announces it will close its Singapore vaccine manufacturing facility by February 2027 as declining Covid revenues drive a strategic pivot, and Pharmaceutical Executive examines two emerging frameworks that specialty drug manufacturers are using to protect patient access and benefit savings in a shifting payer environment.

Reliable, domain-specific AI models grounded in validated clinical evidence are emerging as essential to safely scaling generative AI across healthcare applications.

BioNTech’s decision to close its Singapore manufacturing facility reflects mounting financial pressure, ongoing restructuring efforts, and uncertainty around the pace at which next-generation mRNA therapies will scale.

Neurocrine Biosciences’ planned $2.9 billion acquisition of Soleno Therapeutics includes the addition of Vykat XR, the first FDA-approved treatment for hyperphagia in Prader-Willi syndrome.

Imunon’s CEO discusses how FDA allowing the Bayesian method impacts innovation in the clinical trial space.

Phenomix CEO Mark Bagnall discusses the reasons for GLP-1 failure and why it’s common for patients to stop taking the medication.